PATENTS

Epigenetic drugs

    Recent patents for pharmaceutical compounds comprising and treatments using histone deacetylase and DNA methyltransferase inhibitors.

    Patent number Description Assignee Inventor Date
    US 10,576,066 A method for modulating programmed death receptor ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also, a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a HDAC inhibitor and a composition comprising a therapeutically effective amount of a PDL1 inhibitor, a programmed death 1 receptor inhibitor, or a combination thereof. H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA) Villagra AV, Sotomayor EM 3/3/2020
    US 10,544,156 A compound or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNA methyltransferase inhibitor, in particular in the treatment of cancer. Pierre Fabre Medicament (Boulogne-Billancourt, France), Centre National de la Recherche Scientifique (Paris) Halby L, Menon Y, Kaloun EB, Long C, Arimondo PB 1/28/2020
    US 10,537,535 Compounds that act as HDAC inhibitors and can affect expression of genes in vivo and in vitro. Such inhibitors can be used as therapeutics for numerous disease conditions, such as a variety of cancers, neural degenerative diseases, neurological diseases, senescence and infectious diseases. The Regents of the University of California (Oakland, CA, USA) Ray A, Yamanaka S 1/21/2020
    US 10,538,498 Novel compounds having HDAC6 inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. Chong Kun Dang Pharmaceutical (Seoul) Lee J, Han Y, Kim Y, Choi D, Min J, Bae M, Yang H, Kim D 1/21/2020
    US 10,532,053 A 4-arylamino quinazoline hydroxamic acid compound having a HDAC inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a HDAC inhibitor medicine. Guangdong Zhongsheng Pharmaceutical (Guangdong, China) Chen L, Long C, Chen X, Liu Z, Ye H, Xie C 1/14/2020
    US 10,533,003 Polyheteroaryl HDAC inhibitors. Karus Therapeutics (Oxfordshire, UK) Shuttleworth SJ, Cecil AR, MacCormick S, Nodes WJ, Tomassi CD, Silva FA 1/14/2020
    US 10,519,149 Compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, that are useful in the treatment of conditions associated with inhibition of histone deacetylase (e.g., HDAC2). Rodin Therapeutics (Boston) Fuller NO, Lowe JA III 12/31/2019
    US 10,508,122 Novel hydroxamic acids that are specific HDAC inhibitors and/or TTK/Mps1 kinase inhibitors, including pharmaceutically acceptable salts thereof, that are useful for modulating HDAC and/or TTK/Mps1 kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. The Regents of the University of Colorado (Denver) Liu X, Zhang G, Chan DC-F, Piscopio AD 12/17/2019
    1. Source: United States Patent and Trademark Office (http://www.uspto.gov).

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Epigenetic drugs. Nat Biotechnol 38, 558 (2020). https://doi.org/10.1038/s41587-020-0523-2

    Download citation

    Search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing